FM
VRTX icon

Freemont Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Freemont Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,200
Closed -$2.04M – 134
2025
Q3 		$2.04M Buy
+5,200
New +$2.17M 1.02% 28
2021
Q4 		– Sell
-32,000
Closed -$5.8M – 116
2021
Q3 		$5.8M Buy
+32,000
New +$6.25M 0.77% 58

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Freemont Management's VRTX Position: Q1 2026 in Review

Freemont Management reduced its Vertex Pharmaceuticals (VRTX) stake by 9.7% in Q1 2026, selling an estimated $326K and leaving 6,500 shares worth $2.9M. The position accounts for 0.44% of the portfolio, ranked #73.

Freemont Management first reported a position in VRTX in Q4 2020 and has held it in 20 quarters since. The position peaked at $20.3M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Freemont Management held 6,500 shares of Vertex Pharmaceuticals worth $2.9M as of Q1 2026.
  • Freemont Management sold 700 Vertex Pharmaceuticals shares in Q1 2026, an estimated $326K.
  • Vertex Pharmaceuticals made up 0.44% of Freemont Management's portfolio in Q1 2026, its #73 holding.
  • Freemont Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
  • Freemont Management's Vertex Pharmaceuticals position peaked at $20.3M in Q2 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Freemont Management's 13F filing for Q1 2026, filed 6 May 2026.